Roy Buchanan
Stock Analyst at JMP Securities
(0.82)
# 3,624
Out of 4,829 analysts
60
Total ratings
26.79%
Success rate
-24.02%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $46 → $47 | $19.43 | +141.89% | 3 | May 9, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $33 → $31 | $9.85 | +214.72% | 6 | May 7, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.20 | +67.36% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.94 | +827.84% | 3 | Mar 14, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $3.62 | +341.99% | 8 | Feb 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $52.50 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $0.80 | +400.69% | 3 | Feb 11, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $21 | $5.56 | +278.04% | 12 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.73 | +1,807.88% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.40 | +415.63% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $7 | $1.34 | +422.39% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.35 | +49.25% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $560.90 | -20.13% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $11.86 | +34.91% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.79 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $2.85 | +14,636.84% | 1 | Sep 14, 2021 |
Cidara Therapeutics
May 9, 2025
Maintains: Market Outperform
Price Target: $46 → $47
Current: $19.43
Upside: +141.89%
Dynavax Technologies
May 7, 2025
Maintains: Market Outperform
Price Target: $33 → $31
Current: $9.85
Upside: +214.72%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.20
Upside: +67.36%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.94
Upside: +827.84%
CureVac
Feb 14, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $3.62
Upside: +341.99%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $52.50
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $0.80
Upside: +400.69%
Enanta Pharmaceuticals
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $5.56
Upside: +278.04%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.73
Upside: +1,807.88%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.40
Upside: +415.63%
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.34
Upside: +422.39%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.35
Upside: +49.25%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $560.90
Upside: -20.13%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $11.86
Upside: +34.91%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.79
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $2.85
Upside: +14,636.84%